CG Oncology’s Strategic Advancements and Promising Data Reinforce Buy Rating

Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on CG Oncology, Inc. and keeping the price target at $75.00.

Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight CG Oncology’s promising advancements and strategic positioning in the market. The company’s recent updates indicate that the submission for cretostimogene in BCG-unresponsive HR-NMIBC is progressing as planned, with significant data expected by the end of 2025. The maturing BOND-003 dataset reveals a strong median duration of response, supported by a consistent immunologic profile, which suggests long-term immune surveillance and disease control.
Furthermore, operational improvements such as simplifying the administration process and enhancing the stability of the product are likely to facilitate broader adoption in urology practices. The absence of severe treatment-related adverse events and the highest long-term complete response rates in the patient population underscore the therapy’s potential advantages over competitors. These factors, combined with accelerated trial enrollments and the potential for market education through competitive entries, reinforce the Buy rating as cretostimogene could become a best-in-class therapy option for HR-NMIBC.

In another report released on August 8, Bank of America Securities also reiterated a Buy rating on the stock with a $62.00 price target.